谷红注射液治疗冠状动脉微血管功能障碍的临床研究  

Clinical Study on Guhong Injection in the Treatment of Coronary Microvascular Dysfunction

作　　者：张浩波 伍啟华 赖婷 王淑芬 蔡海荣[2] 陈立[2] 陈伯钧[2,4] 李庆敏[5] ZHANG Haobo;WU Qihua;LAI Ting;WANG Shufen;CAI Hairong;CHEN Li;CHEN Bojun;LI Qingmin(Foshan Hospital of Traditional Chinese Medicine,Foshan 528000 Guangdong,China;Guangdong Provincial Hospital of Chinese Medicine,Guangzhou 510120 Guangdong,China;Dongguan Maternal and Child Health Care Hospital,Dongguan 523000 Guangdong,China;Clinical Research Team for Prevention and Treatment of Cardiovascular Emergency with Traditional Chinese Medicine,Guangdong Provincial Hospital of Chinese Medicine,Guangzhou 510120 Guangdong,China;Chenzhou First People's Hospital,Chenzhou 423099 Hunan,China)

机构地区：[1]佛山市中医院,广东佛山528000 [2]广东省中医院,广东广州510120 [3]东莞市妇幼保健院,广东东莞523000 [4]广东省中医院中医药防治心血管急症临床研究团队,广东广州510120 [5]郴州市第一人民医院,湖南郴州423099

出　　处：《广州中医药大学学报》2025年第1期44-50,共7页Journal of Guangzhou University of Traditional Chinese Medicine

基　　金：国家自然科学基金面上项目(编号:82074342);广州市科技计划项目(编号:202201020352)。

摘　　要：【目的】探讨谷红注射液治疗冠状动脉微血管功能障碍(CMD)气滞血瘀证患者的临床疗效。【方法】将2021年6月至2022年8月广东省中医院收治的60例CMD气滞血瘀证患者按随机数字表法随机分为对照组和试验组,每组各30例。对照组给予西医常规治疗,试验组在对照组的基础上联合谷红注射液治疗,疗程为10 d。观察2组患者治疗前后中医证候积分、血脂指标及血清炎症因子、内皮因子水平的变化情况,并评价2组患者的临床疗效。【结果】(1)脱落情况方面,研究过程中,对照组脱落3例,试验组脱落2例,最终共有55例患者纳入疗效统计分析(其中对照组27例,试验组28例)。(2)疗效方面,治疗10 d后,试验组的总有效率为89.29%(25/28),对照组为40.74%(11/27),组间比较(χ^(2)检验),试验组的疗效明显优于对照组(P<0.01)。(3)中医证候积分方面,治疗后,2组患者的中医证候积分均较治疗前下降(P<0.05),且试验组对中医证候积分的下降幅度明显优于对照组(P<0.01)。(4)血脂指标方面,治疗后,2组患者的甘油三酯(TG)、总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)水平均较治疗前下降(P<0.05),高密度脂蛋白胆固醇(HDL-C)水平均较治疗前升高(P<0.05),且试验组对TG、TC、LDL-C水平的下降幅度及对HDL-C水平的升高幅度均明显优于对照组(P<0.05或P<0.01)。(5)炎症因子方面,治疗后,2组患者的血清超敏C反应蛋白(hs-CRP)、白细胞介素6(IL-6)、肿瘤坏死因子α(TNF-α)水平均较治疗前下降(P<0.05),且试验组对血清hs-CRP、IL-6、TNF-α水平的下降幅度均明显优于对照组(P<0.01)。(6)内皮因子方面,治疗后,2组患者的血清一氧化氮(NO)水平均较治疗前升高(P<0.05),血清内皮素1(ET-1)水平均较治疗前下降(P<0.05),且试验组对血清NO水平的升高幅度及对血清ET-1水平的下降幅度均明显优于对照组(P<0.05或P<0.01)。【结论】在西医常规治疗基础上联合谷红注射�Objective To investigate the clinical efficacy of Guhong Injection for the treatment of patients with coronary microvascular dysfunction(CMD)of qi stagnation and blood stasis syndrome.Methods Sixty cases of patients with CMD of qi stagnation and blood stasis syndrome who were admitted to Guangdong Provincial Hospital of Chinese Medicine from June 2021 to August 2022 were randomly divided into the control group and the trial group according to the random number table method,with 30 cases in each group.The control group was treated with conventional western medicine,and the trial group was treated with Guhong Injection on the basis of treatment for the control group.The course of treatment for the two groups covered 10 days.The changes in traditional Chinese medicine(TCM)syndrome scores,and levels of lipid indicators,serum inflammatory factors and endothelial factors in the two groups were observed before and after treatment.After treatment,the clinical efficacy of the two groups was evaluated.Results(1)During the trial,three cases in the control group and two cases in the trial group fell off and a total of 55 cases were finally included in the statistical analysis of efficacy,including 27 cases in the control group and 28 cases in the trial group.(2)After 10 days of treatment,the total effective rate of the trial group was 89.29%(25/28),and that of the control group was 40.74%(11/27),and the intergroup comparison(tested by chi-square test)showed that the therapeutic efficacy of the trial group was significantly superior to that of the control group(P<0.01).(3)After treatment,the TCM syndrome scores of patients in both groups were decreased compared with those before treatment(P<0.05),and the decrease in the trial group was significantly superior to that in the control group(P<0.01).(4)After treatment,the levels of lipid indicators triglyceride(TG),total cholesterol(TC),and low-density lipoprotein cholesterol(LDL-C)in the two groups of patients were decreased compared with those before treatment(P<0.05),and the le

关 键 词：冠状动脉微血管功能障碍 气滞血瘀证 谷红注射液 炎症反应 内皮功能 临床疗效 

分 类 号：R259.414[医药卫生—中西医结合]